Since heat shock protein 90 (Hsp90) is highly overexpressed in cancer, it is considered both a tumor marker and a therapeutic target for intervention.

Microtubules need to maintain a dynamic balance between polymerization and depolymerization to accomplish their role in cell division and other functions. Classical tubulin-targeting agents are divided into microtubule stabilizers and tubulin polymerization inhibitors.

Hypoxia, a hallmark of the tumor microenvironment (TME), promotes malignant progression and resistance to chemotherapy and radiotherapy and hence, should be delimitated before treatment initiation. 

Shigella flexneri is the leading cause of endemic diarrhea and dysentery in some countries with low-to-middle incomes. There is still a lack of a licensed vaccine against this pathogen.

The first development candidate has been nominated under a collaboration between Carisma Therapeutics Inc. and Moderna Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocytes and macrophages (CAR-M) therapeutics for the treatment of cancer.

NLS Pharmaceutics Ltd. has announced preclinical results from in vitro studies targeting α-synuclein, specifically the A53T mutation, demonstrating the potential of Aexon Labs Inc.’s compounds for Parkinson’s disease.